**6. References**

Abelmann WH. (1971). Virus and the heart. *Circulation* 44, 950-956.


Viral-induced protein cleavage and host protein degradation dysregulation play important roles in the pathogenesis of viral myocarditis and its subsequent progression to DCM. Identification of viral-induced protein cleavage fragments may allow early diagnosis of viral myocarditis, which opens up the optimal treatment window. A combination of antiviral therapies including specific viral protease inhibitors, proteasome inhibitors, and autophagy inhibitors presents new strategies for effective early viral clearance and minimization of viral-induced, inflammation-associated damage. Further studies employing system-like approaches, such as ubiquitomics, degradomics, and RNAi screens, are required to decipher the complex interactions between host and virus during different stages of viral myocarditis. Efforts in clarifying the precise functions and regulatory mechanisms of the host protein degradation systems in the disease progression of viral myocarditis will lead to novel

Badorff C & Knowlton KU. (2004). Dystrophin disruption in enterovirus-induced

Badorff C, Lee GH, Lamphear BJ, Martone ME, Campbell KP, Rhoads RE & Knowlton KU.

Baughman KL. (2006). Diagnosis of myocarditis: death of Dallas criteria. *Circulation* 113, 593-

Calabrese F, Carturan E & Thiene G. (2010). Cardiac infections: focus on molecular

Chang J, Wei L, Otani T, Youker KA, Entman ML & Schwartz RJ. (2003). Inhibitory cardiac

failure and attenuated by ventricular unloading. *Circulation* 108, 407-413. Chau DH, Yuan J, Zhang H, Cheung P, Lim T, Liu Z, Sall A & Yang D. (2007).

Davis FJ, Gupta M, Pogwizd SM, Bacha E, Jeevanandam V & Gupta MP. (2002). Increased

de Breyne S, Bonderoff JM, Chumakov KM, Lloyd RE & Hellen CU. (2008). Cleavage of

Deconinck AE, Rafael JA, Skinner JA, Brown SC, Potter AC, Metzinger L, Watt DJ, Dickson

Dengjel J, Schoor O, Fischer R, Reich M, Kraus M, Muller M, Kreymborg K, Altenberend F,

failing hearts. *Am J Physiol Heart Circ Physiol* 282, H1521-1533.

disruption in an acquired cardiomyopathy. *Nat Med* 5, 320-326.

myocarditis and dilated cardiomyopathy: from bench to bedside. *Med Microbiol* 

(1999). Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal

transcription factor, SRF-N, is generated by caspase 3 cleavage in human heart

Coxsackievirus B3 proteases 2A and 3C induce apoptotic cell death through mitochondrial injury and cleavage of eIF4GI but not DAP5/p97/NAT1. *Apoptosis*

expression of alternatively spliced dominant-negative isoform of SRF in human

eukaryotic initiation factor eIF5B by enterovirus 3C proteases. *Virology* 378, 118-122.

JG, Tinsley JM & Davies KE. (1997). Utrophin-dystrophin-deficient mice as a model

Brandenburg J, Kalbacher H, Brock R, Driessen C, Rammensee HG & Stevanovic S.

therapeutic targets to improve treatment in different disease stages.

Abelmann WH. (1971). Virus and the heart. *Circulation* 44, 950-956.

diagnosis. *Cardiovasc Pathol* 19, 171-182.

Cooper LT, Jr. (2009). Myocarditis. *N Engl J Med* 360, 1526-1538.

for Duchenne muscular dystrophy. *Cell* 90, 717-727.

**5. Conclusion** 

**6. References** 

595.

12, 513-524.

*Immunol* 193, 121-126.

(2005). Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. *Proc Natl Acad Sci U S A* 102, 7922-7927.


Impaired Cardiac Function in Viral Myocarditis 307

Niu Z, Li A, Zhang SX & Schwartz RJ. (2007). Serum response factor micromanaging

Oka T, Xu J & Molkentin JD. (2007). Re-employment of developmental transcription factors

Okuni M, Yamada T, Mochizuki S & Sakurai I. (1975). Studies on myocarditis in childhood,

Parlakian A, Charvet C, Escoubet B, Mericskay M, Molkentin JD, Gary-Bobo G, De Windt LJ,

Parlakian A, Tuil D, Hamard G, Tavernier G, Hentzen D, Concordet JP, Paulin D, Li Z &

Porrello ER, D'Amore A, Curl CL, Allen AM, Harrap SB, Thomas WG & Delbridge LM.

Powell SR, Samuel SM, Wang P, Divald A, Thirunavukkarasu M, Koneru S, Wang X &

Predmore JM, Wang P, Davis F, Bartolone S, Westfall MV, Dyke DB, Pagani F, Powell SR &

Ravikumar B, Sarkar S, Davies JE, Futter M, Garcia-Arencibia M, Green-Thompson ZW,

Razeghi P, Baskin KK, Sharma S, Young ME, Stepkowski S, Essop MF & Taegtmeyer H.

Reyes MP & Lerner AM. (1985). Coxsackievirus myocarditis--with special reference to acute

Rivett AJ & Hearn AR. (2004). Proteasome function in antigen presentation:

Seipelt J, Liebig HD, Sommergruber W, Gerner C & Kuechler E. (2000). 2A proteinase of

Si X, Gao G, Wong J, Wang Y, Zhang J & Luo H. (2008). Ubiquitination is required for

Si X, McManus BM, Zhang J, Yuan J, Cheung C, Esfandiarei M, Suarez A, Morgan A & Luo

effective replication of coxsackievirus B3. *PLoS One* 3, e2585.

mediated cardiomyocyte autophagy. *Hypertension* 53, 1032-1040.

experimental hyperglycemia. *J Mol Cell Cardiol* 44, 618-621.

dilated cardiomyopathies. *Circulation* 121, 997-1004.

and chronic effects. *Prog Cardiovasc Dis* 27, 373-394.

pathophysiology. *Physiol Rev* 90, 1383-1435.

proteins. *Curr Protein Pept Sci* 5, 153-161.

replication. *J Virol* 81, 3142-3150.

with special reference to the possible role of immunological process and the

Ludosky MA, Paulin D, Daegelen D, Tuil D & Li Z. (2005). Temporally controlled onset of dilated cardiomyopathy through disruption of the SRF gene in adult heart.

Daegelen D. (2004). Targeted inactivation of serum response factor in the developing heart results in myocardial defects and embryonic lethality. *Mol Cell* 

(2009). Angiotensin II type 2 receptor antagonizes angiotensin II type 1 receptor-

Maulik N. (2008). Upregulation of myocardial 11S-activated proteasome in

Day SM. (2010). Ubiquitin proteasome dysfunction in human hypertrophic and

Jimenez-Sanchez M, Korolchuk VI, Lichtenberg M, Luo S, Massey DC, Menzies FM, Moreau K, Narayanan U, Renna M, Siddiqi FH, Underwood BR, Winslow AR & Rubinsztein DC. (2010). Regulation of mammalian autophagy in physiology and

(2006). Atrophy, hypertrophy, and hypoxemia induce transcriptional regulators of the ubiquitin proteasome system in the rat heart. *Biochem Biophys Res Commun* 342,

immunoproteasome complexes, Peptide production, and interactions with viral

human rhinovirus cleaves cytokeratin 8 in infected HeLa cells. *J Biol Chem* 275,

H. (2005). Pyrrolidine dithiocarbamate reduces coxsackievirus B3 replication through inhibition of the ubiquitin-proteasome pathway. *J Virol* 79, 8014-8023. Si X, Wang Y, Wong J, Zhang J, McManus BM & Luo H. (2007). Dysregulation of the

ubiquitin-proteasome system by curcumin suppresses coxsackievirus B3

cardiogenesis. *Curr Opin Cell Biol* 19, 618-627.

*Circulation* 112, 2930-2939.

*Biol* 24, 5281-5289.

361-364.

20084-20089.

in adult heart disease. *Semin Cell Dev Biol* 18, 117-131.

thymus in the chronicity of the disease. *Jpn Circ J* 39, 463-470.


Jackson WT, Giddings TH, Jr., Taylor MP, Mulinyawe S, Rabinovitch M, Kopito RR &

Jakel S, Kuckelkorn U, Szalay G, Plotz M, Textoris-Taube K, Opitz E, Klingel K, Stevanovic

viruses. *PLoS Biol* 3, e156.

*Pathol* 163, 381-385.

*Life Sci* 65, 3971-3980.

*Cardiovasc Res* 60, 5-10.

*Apoptosis* 3, 309-315.

injury. *Cardiovasc Clin* 18, 163-184.

expression. *J Mol Cell Cardiol* 35, 577-593.

Kirkegaard K. (2005). Subversion of cellular autophagosomal machinery by RNA

S, Kandolf R, Kotsch K, Stangl K, Kloetzel PM & Voigt A. (2009). Differential interferon responses enhance viral epitope generation by myocardial immunoproteasomes in murine enterovirus myocarditis. *Am J Pathol* 175, 510-518. Kaab S, Barth AS, Margerie D, Dugas M, Gebauer M, Zwermann L, Merk S, Pfeufer A,

Steinmeyer K, Bleich M, Kreuzer E, Steinbeck G & Nabauer M. (2004). Global gene expression in human myocardium-oligonucleotide microarray analysis of regional diversity and transcriptional regulation in heart failure. *J Mol Med* 82, 308-316. Kemball CC, Alirezaei M, Flynn CT, Wood MR, Harkins S, Kiosses WB & Whitton JL. (2010).

Coxsackievirus infection induces autophagy-like vesicles and megaphagosomes in

inhibition reduces coxsackievirus B3 replication in murine cardiomyocytes. *Am J* 

Beisel KW & Kandolf R. (1993). Direct myocardial injury by enterovirus: a central role in the evolution of murine myocarditis. *Clin Immunol Immunopathol* 68, 159-169.

Stangl K. (2008). Suppression of cardiomyocyte hypertrophy by inhibition of the

heightened expectations, unfulfilled promises and broken hearts em leader.

H, Bishop K, Yonekawa H, Tamura T, Kaisho T, Taya C, Taniguchi T & Honda K. (2008). A critical link between Toll-like receptor 3 and type II interferon signaling pathways in antiviral innate immunity. *Proc Natl Acad Sci U S A* 105, 20446-20451. Nigro G, Comi LI, Politano L & Bain RJ. (1990). The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. *Int J Cardiol* 26, 271-277.

Levine B & Kroemer G. (2008). Autophagy in the pathogenesis of disease. *Cell* 132, 27-42. Luo H, Wong J & Wong B. (2010). Protein degradation systems in viral myocarditis leading

Luo H, Zhang J, Cheung C, Suarez A, McManus BM & Yang D. (2003). Proteasome

Mao I, Liu J, Li X & Luo H. (2008). REGgamma, a proteasome activator and beyond? *Cell Mol* 

Mason JW. (2003). Myocarditis and dilated cardiomyopathy: an inflammatory link.

McManus BM, Chow LH, Wilson JE, Anderson DR, Gulizia JM, Gauntt CJ, Klingel KE,

McManus BM, Gauntt CJ & Cassling RS. (1988). Immunopathologic basis of myocardial

Meiners S, Dreger H, Fechner M, Bieler S, Rother W, Gunther C, Baumann G, Stangl V &

Miano JM. (2003). Serum response factor: toggling between disparate programs of gene

Murray BW, Sultmann H & Klein J. (2000). Identification and linkage of the proteasome activator complex PA28 subunit genes in zebrafish. *Scand J Immunol* 51, 571-576. Narula J, Chandrasekhar Y & Dec GW. (1998). Apoptosis in heart failure: a tale of

Negishi H, Osawa T, Ogami K, Ouyang X, Sakaguchi S, Koshiba R, Yanai H, Seko Y, Shitara

pancreatic acinar cells in vivo. *J Virol* 84, 12110-12124.

to dilated cardiomyopathy. *Cardiovasc Res* 85, 347-356.

ubiquitin-proteasome system. *Hypertension* 51, 302-308.


**15** 

*Japan* 

**Experimental Autoimmune Myocarditis:** 

*1Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata* 

*2Department of Functional and Analytical Food Sciences, Niigata University of Pharmacy* 

Myocarditis is defined as myocardial inflammation allied with edema, cellular infiltration, apoptosis and necrosis of cardiomyocytes (Rosenstein et al., 2000). It is likely to be a complex disease and its etiology has been associated with various infections, systemic diseases, drugs, and toxins. Among them, a wide array of organisms, including viral, bacterial, rickettsial, fungal, and parasitic organisms have been implicated as causative agents (Feldman & McNamara, 2000). There are two types of myocarditis viz, lymphocytic

Acute myocarditis must be considered in patients who present with recent onset of cardiac failure or arrhythmia, though the onset of clinical cardiac symptoms may be vague in many patients. Fulminant myocarditis is a distinct entity characterized by the sudden onset of severe congestive heart failure or cardiogenic shock, usually following a flu-like illness. Giant cell myocarditis is a rare, frequently fatal disorder of unknown origin characterized by the presence of giant cell inflammatory infiltrate in the myocardium with widespread necrosis and degeneration of myocardial fibers (Batra & Lewis, 2001). It may be associated

Heart reactive autoantibodies are found in a high percentage of patients with myocarditis. Identified autoantigens include the β1 adrenoreceptor adenine dinucleotide translocator, branched-chain keto acid dehydrogenase, cardiac myosin, sarcolemmal and myolemmal proteins, connective tissue, and extracellular matrix proteins including laminin. Antigenic mimicry between the dominant self molecules and the infectious agents also contributes to

The EAM model has been extensively used as a disease model of human myocarditis (Kodama et al., 1990). Experimental data revealed several similarities between this model

with various systemic autoimmune diseases (Kuhl & Schultheiss, 2010).

the disease process (Caforio et al., 1997; Neumann et al., 1990; Maisch, 1989).

**2. Experimental autoimmune myocarditis (EAM)** 

**1. Introduction** 

and giant cell myocarditis.

**Role of Renin Angiotensin System** 

Kenichi Watanabe1, Somasundaram Arumugam1, Rajarajan A. Thandavarayan1,2 and Makoto Kodama3

*University of Pharmacy and Applied Life Sciences, Niigata,* 

*3First Department of Medicine, Niigata University Graduate* 

*School of Medical and Dental Sciences, Niigata,* 

*and Applied Life Sciences, Niigata,* 

